Clinical trials: Hepatitis B Viral Infection
Chronic Hepatitis C, Chronic Hepatitis B
The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study
This study aims to demonstrate that patients with chronic hepatitis C (CHC) and B (CHB) experiencing regression of liver cirrhosis after effective antiviral therapy have decreased risk for hepatocellular carcinoma (HCC).
- Trial name
- ROLFH (NCT01831037)
- Testing
- Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
- Where
- 4 sites in United States, Canada
- Sponsor
- University of Arkansas
Hepatitis B, Chronic
Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients
The purpose of this study is to evaluate the antiviral activity and safety of EntecaBell ODT. in chronic hepatitis B Patients.
- Trial name
- NCT02588937
- Testing
- EntecaBell ODT. 0.5mg, Baraclude Tab. 0.5mg
- Where
- 9 sites in South Korea
- Volunteers
- 76 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Chronic Hepatitis B
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.
- Trial name
- NCT03585322
- Testing
- APG-1387 for Injection
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Ascentage Pharma Group Inc.
Liver Failure, Hepatitis B
RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure
This study evaluates the Granulocyte colony-stimulating factor (G-CSF) in the treatment of Acute on Chronic Liver Failure in adult.
- Conditions
- Liver Failure, Hepatitis B, Alcoholic Liver Disease
- Trial name
- NCT02331745
- Testing
- Granulocyte colony-stimulating factor, standard treatment
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Beijing 302 Hospital
Diphtheria, Hepatitis B
Pentavalent DTaP-Hep B-IPV
The purpose of this study is to evaluate the safety of administering a combination vaccine (DTaP-HepB-IPV; Pediarix™) to infants at birth, 2 and 6 months compared to the administration of a HepB vaccine at birth and the same…
- Conditions
- Diphtheria, Hepatitis B, Poliomyelitis, Pertussis
- Trial name
- NCT00133445
- Testing
- DTaP-Hep B-IPV Vaccine, Monovalent Hep B Vaccine
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B, HIV
Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .
Hepatitis B virus infection is a common occurrence among patients with HIV. Effective vaccines are available, but there's some uncertainty regarding specific dosages, specially among those who have not responded to an initial…
- Trial name
- CORE-HIV (NCT02003703)
- Testing
- Recombinant Hepatitis B Virus Vaccine
- Where
- Chile
- Volunteers
- 107 people
- Sponsor
- Universidad de Valparaiso
Hepatitis E
HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
Hepatitis E is the fifth known human viral hepatitis and is probably the most common cause of acute viral hepatitis in the world.
- Trial name
- NCT03488589
- Testing
- serum samples for HEV RNA PCR
- Volunteers
- 150 people
- Sponsor
- Mahmoud Abdel Rahman
Hepatitis B
This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa
The purpose of this study is to assess the long-term persistence of immunity to hepatitis B in adolescents aged 12-13 years who were vaccinated with four doses of Infanrix™-Hexa in infancy and to assess the anamnestic response…
- Trial name
- NCT02052661
- Testing
- Engerix™-B Kinder
- Where
- 11 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B Treated With Nucleoside/Nucleotide Analogues
Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs
Define the patients who lost HBsAg, studying the loss predictive factors and if there was suspension of treatment, study the evolution after that
- Trial name
- NCT02005146
- Where
- 22 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Hepatitis B, Tenofovir
Tenofovir in Pregnancy to Prevent Mother to Child Transmission of Hepatitis B.
Hepatitis B virus (HBV) can be asymptomatic for years but can also lead to chronic hepatitis, hepatocellular carcinoma, and liver failure and death and cannot be eradicated with the current therapy.
- Conditions
- Hepatitis B, Tenofovir, Pregnancy
- Trial name
- PK-TDF (NCT04114890)
- Testing
- Tenofovir Disoproxil Fumarate
- Where
- Thailand
- Volunteers
- 27 people
- Sponsor
- University of Oxford
CHRONIC HEPATITIS B
Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B
Phyllanthus Urinaria - Adenosma Glutinosum - Eclipta Prostrata - Ascorbic Acid combination plus Tenofovir in treatment of acute and chronic hepatitis B.
- Trial name
- HBV (NCT01198860)
- Testing
- CTH Chronic Hepatitis B
- Where
- 2 sites in United States, Vietnam
- Sponsor
- Nguyen Thi Trieu, MD
Chronic Hepatitis b
The Effect of Metabolic Syndrome on Antiviral Response in People With Chronic Hepatitis B
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major…
- Trial name
- NCT05705141
- Volunteers
- 1,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
HBV Treatment Adherence by Support Program
A Nationwide Epidemiological, Educational Support Program for Improving Treatment Adherence in Patients With HBV
Protocol Title: A Nationwide Epidemiological, Non-Interventional Study Evaluating an Educational Support Program for Improving Treatment Adherence in Patients with Hepatitis B Viral Infection Objective(s): The primary objectives…
- Trial name
- Help-B (NCT01991262)
- Sponsor
- Carmel Medical Center
HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV)
Combating Related Epidemics in HCV
This is a two-arm cluster randomized control trial to evaluate the effectiveness of a single-visit point-of-care (POC) test and treat bundle (intervention arm) compared to the current standard-of-care (SOC, control arm).
- Conditions
- HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV), HEPATITIS C (HCV)
- Trial name
- CREST (NCT07560046)
- Testing
- Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2
- Volunteers
- 1,280 people
- Sponsor
- Duke University
HIV Infections, Hepatitis B
Hepatitis B Vaccination in HIV-infected Persons
In this study we compare the efficacy of two different HBV-vaccination schedules in HIV-infected persons concerning immune response and compliance. Short schedule: t=0,1,3 weeks and standard schedule: t=0,1,6 months.
- Trial name
- NCT00230061
- Testing
- HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml
- Where
- Netherlands
- Volunteers
- 800 people
- Sponsor
- Erasmus Medical Center
Chronic Hepatitis B
Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B
The study is an open-label, randomized, comparative, multicenter clinical trial. The purpose of this study is to assess the efficacy of ABX203, a new chronic hepatitis B therapeutic vaccine administered as an adjunct therapy to…
- Trial name
- NCT02249988
- Testing
- ABX203 therapeutic Hepatitis B vaccine treatment arm
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 261 people
- Sponsor
- Abivax S.A.
Hepatitis B
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
This study is conducted to assess safety and immunogenicity of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system in healthy, HBs naïve, adults aged 18-45 years and to differentiate GSK's AS37 adjuvant system from…
- Trial name
- NCT05561673
- Testing
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system, GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
- Where
- 5 sites in Belgium, Germany and 1 more
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cirrhosis, Alcohol Related Liver Disease
Clinical Characteristics of Recompensation
Recompensation in decompensated liver cirrhosis is an emerging clinical endpoint; however, standardized criteria and long-term prognostic data are currently lacking.
- Conditions
- Cirrhosis, Alcohol Related Liver Disease, HBV (Hepatitis B Virus), Recompensation
- Trial name
- NCT07651683
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis B
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
In this cohort study, patients with chronic hepatitis B who prior participated in TB1211IFN study and received at least 39 doses of peginterferon alfa will be enrolled.
- Trial name
- NCT03181113
- Testing
- Peginterferon Alfa-2B, Peginterferon Alfa-2A
- Where
- 28 sites in China
- Volunteers
- 473 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Hepatitis B, Hepatitis D
Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus
Background: Sudan has a high prevalence of hepatitis B surface antigen (HBsAg), exceeding 8%. The prevalence of hepatitis B varies across different regions of Sudan, ranging from 6.8% in central Sudan to as high as 26% in…
- Conditions
- Hepatitis B, Hepatitis D, Viral Hepatitis
- Trial name
- NCT06360484
- Testing
- investigations for Hepatitis D virus
- Where
- Sudan
- Volunteers
- 90 people
- Sponsor
- National Center for Gastroentestinal and Liver Disease